Dirk Thye insider trades

Open-market stock purchases and sales by Dirk Thye, CEO and CMO at Quince Therapeutics, Inc, from SEC Form 4 filings since Mar 16, 2016.

Track record: 50% of 4 scored buys are up 5% or more since purchase, averaging +12%.

Recent trades

DateStockTradeValue
Jan 23, 2026QNCX Quince Therapeutics, IncBought (not open market)—
Dec 10, 2025QNCX Quince Therapeutics, IncBought (not open market)—

Companies traded

  • QNCX Quince Therapeutics, Inc: 4 buys, last Jan 23, 2026
  • CRTX Cortexyme, Inc: other filings, last May 23, 2022
  • CDTX Cidara Therapeutics, Inc: other filings, last Mar 16, 2016

Get free alerts when Dirk Thye files a new trade →